The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
LRRK2 Cohort Working Group, 2011Gait and Motor Symptoms in Healthy Asymptomatic Relatives of Patients with PD Who Are Carriers of Mutations in the LRRK2 Gene
Objective/Rationale:
Gait disturbances play a major role in the motor manifestation of Parkinson's disease (PD). We aim to explore the possibility that subtle gait alterations are also present in the... -
LRRK2 Challenge, 2011Regulation of LRRK2 Activity by Nitric Oxide-Mediated Protein S-Nitrosylation
Objective/Rationale:
Mutations in the LRRK2 gene are a common cause of familial Parkinson’s disease (PD). Familial mutations can influence the GTPase or kinase activity of LRRK2 which may be... -
Rapid Response Innovation Awards, 2012Nigrostriatal Alpha-Synuclein Over-Expression in Young and Aged Pre-Clinical Models
Objective/Rationale:
Accurate pre-clinical models of Parkinson’s disease are needed in order to test novel therapies as well as to further our understanding of the disease itself. The molecule alpha... -
MJFF Research Grant, 2012Generation of Phospho-Ser65 Parkin and Phospho-Thr257 PINK1 Pre-clinical Monoclonal Antibodies and Characterization of Total PINK1 Pre-clinical Monoclonal Antibodies
Objective/Rationale:
Mutations in an enzyme known as PINK1 can cause Parkinson’s disease. There has been
great interest in understanding the function of PINK1 since uncovering the pathways that
PINK1 is... -
MJFF Research Grant, 2012Design of HdAd Type 5 LRRK2 Expression Vectors
Objective/Rationale:
LRRK2 is a gene that is has been implicated in Parkinson’s disease. LRRK2 is a large cDNA of approximately 7.6 kb that precludes it from being expressed in viral vectors such as... -
Therapeutics Development Initiative, 2012Novel Fumarate Esters as Neuroprotective Agents in Parkinson’s Disease
Objective/Rationale:
Fumaric acid esters have shown immuno-modulatory and neuroprotective effects in cell-based systems, pre-clinical models of disease and clinical trials in multiple sclerosis and...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.